Nucleus-Targeted Delivery of Anticancer Drug Using Alpha-Synuclein(Y136C)-Gold Nanoparticle Conjugates

Area of Science:

• Biotechnology
• Nanomedicine
• Cancer Research

Background:

• The cell nucleus is crucial for eukaryotic cell survival and a key target in cancer therapy.
• Conventional nucleus-directed anticancer drugs like doxorubicin (Dox) exhibit limitations in cellular uptake and nuclear delivery.
• Nanoparticle-based systems offer potential solutions for overcoming these drug delivery challenges.

Purpose of the Study:

• To develop an intracellular drug delivery system for nucleus-targeted cancer therapy.
• To utilize alpha-synuclein-gold nanoparticle conjugates (αS-AuNPs) for enhanced drug delivery and nuclear accumulation.
• To achieve controlled drug release using near-infrared (NIR) irradiation and photothermal effects.

Main Methods:

• Conjugation of α-synuclein (αS) with gold nanoparticles (AuNPs) to form αS-AuNPs.
• Linking doxorubicin (Dox) to αS-AuNPs via a heat-labile cross-linker.
• Utilizing NIR irradiation to trigger photothermal effect and induce localized hyperthermia for drug release.
• Evaluating the efficacy of the Dox-αS-AuNP system for nucleus-targeted cancer therapy.

Main Results:

• αS-AuNPs demonstrated efficient cellular uptake and nuclear accumulation.
• NIR irradiation successfully triggered the cleavage of the heat-labile linker, releasing Dox.
• Localized hyperthermia induced by AuNPs facilitated controlled Dox release within the nucleus.
• Enhanced anticancer efficacy was observed with the nucleus-targeted Dox-αS-AuNP system.

Conclusions:

• Dox-αS-AuNP is a promising nucleus-targeted drug delivery system for cancer therapy.
• The system enables controlled and efficient delivery of doxorubicin to the cell nucleus.
• This approach holds potential for improving cancer treatment outcomes by enhancing drug efficacy.